Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamilton Health Sciences Corporation
• Collaborator: AstraZeneca
• Treatments: Budesonide; Fluticasone; Xhance

Criteria

Inclusion Criteria:

• mild asthma

• nonsmokers

• allergen-induced early and late asthmatic response

Exclusion Criteria:

• no medication other than infrequent ( < twice weekly) inhaled beta2-agonists

• not be exposed to sensitizing allergens

• asthma exacerbation or respiratory tract infection in the past4 weeks